Azenta Life Sciences Overview
- Year Founded
-
1978
- Status
-
Public
- Employees
-
2,900
- Stock Symbol
-
AZTA
- Investments
-
49
- Share Price
-
$45.64
- (As of Friday Closing)
Azenta Life Sciences General Information
Description
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
Contact Information
Website
www.azenta.comCorporate Office
- 200 Summit Drive
- Burlington, MA 01803
- United States
Corporate Office
- 200 Summit Drive
- Burlington, MA 01803
- United States
Azenta Life Sciences Stock Performance
As of 13-Nov-2026, Azenta Life Sciences’s stock price is $45.64. Its current market cap is $1.91B with 41.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $45.64 | $43.77 | $15.93 - $50.05 | $1.91B | 41.8M | 1M | -$3.70 |
Azenta Life Sciences Financials Summary
As of 30-Sep-2026, Azenta Life Sciences has a trailing 12-month revenue of $622M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Sep-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 |
|---|---|---|---|---|
| EV | 1,256,645 | 1,256,645 | 1,050,288 | 1,845,027 |
| Revenue | 621,703 | 621,703 | 593,821 | 573,448 |
| EBITDA | (112,316) | (112,316) | 35,287 | 38,728 |
| Net Income | (166,985) | (166,985) | (55,763) | (164,897) |
| Total Assets | 1,708,383 | 1,708,383 | 2,059,582 | 2,100,265 |
| Total Debt | 51,874 | 51,874 | 51,244 | 56,677 |
Azenta Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Azenta Life Sciences Comparisons
Industry
Financing
Details
Azenta Life Sciences Competitors (9)
One of Azenta Life Sciences’s 9 competitors is Bio-Rad Laboratories, a Corporation company based in Hercules, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
| Novogene | Formerly PE-Backed | Beijing, China | ||||
| Liconic Ag | Corporation | Woburn, MA | ||||
| GenScript | Formerly VC-backed | Nanjing, China | ||||
| Integrated DNA Technologies | Formerly PE-Backed | Coralville, IA |
Azenta Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Azenta Life Sciences Patents
Azenta Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183344-A1 | Tube entry guide system and method | Pending | 27-Feb-2025 | ||
| EP-4797322-A1 | Apparatus and method for cleaning a carrier for semiconductor fabrication articles | Pending | 19-Feb-2025 | ||
| WO-2026175537-A1 | Method and apparatus for assessing a quality of a container for at least one semiconductor fabrication article | Pending | 19-Feb-2025 | ||
| EP-4797323-A1 | Methods and systems for measuring contamination of semiconductor carrier devices | Pending | 19-Feb-2025 | ||
| WO-2026175804-A1 | Methods and systems for measuring contamination of semiconductor carrier devices | Pending | 19-Feb-2025 | H10P72/06 |
Azenta Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Azenta Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Azenta Life Sciences Investments & Acquisitions (49)
Azenta Life Sciences’s most recent deal was a Merger/Acquisition with Synplexity. The deal was made on 28-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Synplexity | 28-Oct-2026 | Merger/Acquisition | Biotechnology | ||
| Uk Biocentre | 04-Mar-2026 | Merger/Acquisition | Biotechnology | ||
| Cold Chain Connect Japan | 23-Aug-2025 | Joint Venture | Other Commercial Services | ||
| Ziath | 02-Feb-2023 | Merger/Acquisition | Other Devices and Supplies | ||
| B Medical Systems | 03-Oct-2022 | Merger/Acquisition | Other Devices and Supplies |
Azenta Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
16.95 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Laboratory Equipment and Services
Subindustry
of 67
Rank
Percentile
Azenta Life Sciences Exits (4)
Azenta Life Sciences’s most recent exit was on 03-Oct-2022 from B Medical Systems. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| B Medical Systems | 03-Oct-2022 | Completed |
|
||
| PharmaSeq | 16-Sep-2015 | Completed |
|
||
| Progressive Technologies | 12-Jul-2001 | Completed |
|
||
| Ulvac Cryogenics | 01-Jan-1981 | Joint Venture | Completed |
|
Azenta Life Sciences Affiliates
Subsidiaries (5)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Synplexity | Eugene, OR | 2024 | |
| Uk Biocentre | Milton Keynes, United Kingdom | 2014 | |
| Ziath | Dorking, United Kingdom | 2005 | |
| Genewiz | South Plainfield, NJ | 1999 | |
| Barkey | Leopoldshoehe, Germany | 1980 |
Azenta Life Sciences FAQs
-
When was Azenta Life Sciences founded?
Azenta Life Sciences was founded in 1978.
-
Where is Azenta Life Sciences headquartered?
Azenta Life Sciences is headquartered in Burlington, MA.
-
What is the size of Azenta Life Sciences?
Azenta Life Sciences has 2,900 total employees.
-
What industry is Azenta Life Sciences in?
Azenta Life Sciences’s primary industry is Biotechnology.
-
Is Azenta Life Sciences a private or public company?
Azenta Life Sciences is a Public company.
-
What is Azenta Life Sciences’s stock symbol?
The ticker symbol for Azenta Life Sciences is AZTA.
-
What is the current stock price of Azenta Life Sciences?
As of 13-Nov-2026 the stock price of Azenta Life Sciences is $45.64.
-
What is the current market cap of Azenta Life Sciences?
The current market capitalization of Azenta Life Sciences is $1.91B.
-
What is Azenta Life Sciences’s current revenue?
The trailing twelve month revenue for Azenta Life Sciences is $622M.
-
Who are Azenta Life Sciences’s competitors?
Bio-Rad Laboratories, Novogene, Liconic Ag, GenScript, and Integrated DNA Technologies are some of the 9 competitors of Azenta Life Sciences.
-
What is Azenta Life Sciences’s annual earnings per share (EPS)?
Azenta Life Sciences’s EPS for 12 months was -$3.70.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
